UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2022

Kiromic BioPharma, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-39619**	**46-4762913**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

7707 Fannin Street, Suite 140
Houston, TX **77054**
(Address of principal executive offices) **(Zip Code)**

Registrant's telephone number, including area code: (832) 968-4888
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	KRBP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 11, 2022, Kiromic BioPharma, Inc. (the "Company") made available on its website a revised Company investor presentation. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

In accordance with General Instruction B.2 to Form 8-K, the information contained in this current report, including Exhibit 99.1 hereto, is being "furnished" with the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under such section. Further, such information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits.*

The following documents are herewith filed or furnished as exhibits to this report:

Exhibit Number	Description
99.1	Investor Presentation dated April 11, 2022.
104	Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 11, 2022

KIROMIC BIOPHARMA, INC.

By: /s/ Daniel Clark
Name: Daniel Clark
Title: Interim Chief Financial Officer


KIROMIC
BioPharma
Revolutionizing CAR-T Therapy
April 2022
NASDAQ: KRBP
Kiromic.com

Forward Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

- our goals and strategies;
- our future business development, financial condition and results of operations;
- expected changes in our revenue, costs or expenditures;
- our expected timing of human clinical trials and other related milestones
- growth of and competition trends in our industry;
- our expectations regarding demand for, and market acceptance of, our products;
- our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;
- fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and
- relevant government policies and regulations relating to our industry; and
- the outcome of any pending or threatened litigation.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1 (Registration No. 333-257427) , originally filed with the Securities and Exchange Commission (SEC) on June 25, 2021, as amended, and in our Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on April 8, 2022 and elsewhere in this presentation. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Contents

The Kiromic Difference

Kiromic Biopharma is the only cell therapy company combining genetically edited Gamma Delta CAR-T (GD CAR-T) cells with proprietary targeting technology to address solid malignancies.

[1]American Cancer Society 2020 Cancer Facts & Figures; Leading sites of new cancer cases and deaths; epub.

Strategic Competitive Landscape

6 Known Companies (including Kiromic) in the Gamma Delta CAR-T space.

No Known Competitors with AI-driven Technology Combined with a Gamma Delta CAR-T Cell Delivery Platform.



Solid Malignancy Market Opportunity



[1]Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition, Forecast and Opportunities, 2017-2027 (ReportLinker)
[2]Blood Cancer, Yale Medicine, https://www.yalemedicine.org/conditions/blood-cancers

The Kiromic Competitive Difference

Allogeneic Gamma Delta Based CAR-T Cell Therapies

1 Next Gen Allogeneic Therapy

Allogeneic approach results in simplified and efficient supply chain (vein-to-vein lead time) with improved product availability.

Previous generation of autologous therapy results in manufacturing challenges that made repeat dosing challenging

2 Multi Indication Solid Tumor Therapies

Potential broad treatment for solid malignancies that express Kiromic developed biomarkers such as Isomesothelin.

Solid tumors represent approx. 90% of new cancer cases[1]

3 Superior Safety[2-4]

1. Minimal to no Cytokine Release Syndrome (CRS)

2. Minimal to no Immune Cell Associated Neurotoxicity Syndrome (ICANS)

3. Minimal Graft versus Host Disease (GvHD) therefore no compatibility issues between donors and patients

4 Superior Efficacy[5]

100% efficacy in pre-Clinical animal models

Addressed issues related to low efficacy :

1. Suppressive Tumor micro-environment (TME)
2. T-Cell exhaustion and loss of efficacy

5 In-house Manufacturing

1.No lead time (Off-The-Shelf) vs up to 3-5 weeks for autologous CAR-T such as Kymriah[6]

2. In-house cGMP manufacturing (full control and vertical integration of manufacturing process) including:

a. Unique In-house Vector production
b. Cell therapy production

6 Lower Costs/ Greater Access[7]

1.Outpatient treatment means reduced hospitalization and other treatment related costs – hospitals struggle to break even if given in the inpatient setting

2. **Lower production cost –** competitor costs $373K and $475K per treatment for Yescarta and Kymriah respectively

[1]American Cancer Society 2020 Cancer Facts & Figures; Leading sites of new cancer cases and deaths; epub.
[2]Wang X, et al. Mesothelin isoform 2 is a novel target for allogeneic CAR gamma delta T cell therapy in solid tumors. AACR 2021;Abstract No. 1534
[3]Barber A, et al. Gamma delta T cells engineered with a chimeric PD-1 receptor effectively controls PD-L1 positive tumors in vitro and in vivo with minimal toxicities. AACR 2021; Abstract No.LB148
[4]Xu Y, et al. Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer." Cell Mol Immunol 18(2):427-439.
[5]Parriott G, et al. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. Immunology 160(3):280-294.
[6]NIPS Medicine:Consumer Medicine Information; epub
[7]Maziarz RT. CAR T-cell therapy total cost can exceed $1.5M per treatment. Cell Therapy Next; May 29, 2019.

Contents

Artificial Intelligence and Bioinformatic Analytic Target Discovery, Validation & Development Platform

Algorithms and Large-Scale Genomics Analysis for Target Prediction

Diamond AI™

Artificial Intelligence Neural Network

Machine and deep learning A.I. integrated with each stage of the Kiromic therapy production lifecycle.

The Kiromic Difference - Diamond AI™ Target Discovery Platform

Diamond AI™ target discovery platform powers innovation and significantly reduces development time and cost.



Contents

Gamma Delta T-Cells (GDT): Guardians of the Immune System



GDT CAR-T Cell Therapy Mechanism of Action Targeting PDL-1 Expression In Tumor Tissues



GDT CAR-T Cell Therapy (Procel™ and Isocel™)

Multiple Potential Indications



GDT CAR-T Cell Therapy (Procel™)*
Strong Efficacy

Procel[tm] Eradicates Established NCI-H226 Pleural Epithelioid Mesothelioma and Extends Survival.

Tumor Eradication



Overall Survival



*Preclinical models: nude mice with subcutaneous NCI-H226 cells injections

GDT CAR-T Cell Therapy (Procel™)*
Strong Safety

Procel[tm] Does Not Lead to Cytokine Level Increases Modeled to Cause Severe CRS or CRS, with Circulating Cell Numbers Regulated by Objective Response.



GDT CAR-T Cell Therapy (Isocel™)*
Strong Efficacy

Isocel™ Eradicates Established NCI-H226 Pleural Epithelioid Mesothelioma and Prevents Tumor Growth in a Model Of Recurrence.

Tumor Eradication



Control of recurrence (persistence)



GDT CAR-T Cell Therapy (Isocel™)*
Strong Safety

Isocel™ Does Not Lead to Cytokine Level Increases Modeled to Cause Severe CRS or CRS, with Circulating Cell Numbers Regulated by Objective Response.





*Preclinical models: nude mice with subcutaneous NCI-H226 cells injections

Kiromic's Product Pipeline

Kiromic has developed a robust pipeline of product candidates addressing **solid cancers** utilizing cell therapy with our **GDT CAR-T platform** which has been discovered and validated by our **Diamond AI™** target discovery & validation platform.

Clinical Trial	Indication	Target	Discovery	Pre-Clinical	Phase I
ALEXIS - PRO-1 Procel™ Allogeneic, off-the-shelf GDT CAR-T therapy	**Solid Tumors:** Multi-Indication Dose Escalation PLUS Indication Specific Cohort Expansion	**PD-L1**			**Q4 2022** Expected Beginning of Activation Process for ALEXIS-PRO-1 Clinical Trial
ALEXIS - ISO-1 Isocel™ Allogeneic, off-the-shelf GDT CAR-T therapy	**Solid Tumors:** Multi-Indication Dose Escalation PLUS Indication Specific Cohort Expansion	**Isoform of Mesothelin**			**Q4 2023** Expected Beginning of Activation Process for ALEXIS-ISO-1 Clinical Trial

Contents

Kiromic BioPharma 34,000 sq ft Facility Operations

Contents

Kiromic BioPharma's 2022 Upcoming Milestones*

1 **Completion of cGMP Construction**
- End of Q2 2022

2 **Submission of Amended IND for ALEXIS-PRO-1**
- H2 2022

3 **Expected Beginning of Activation Process for ALEXIS-PRO-1 Clinical Trial**
- End of Q4 2022

*The milestones and timing of completion are based upon the company's current expectations in consultation with its partners and vendors.

Kiromic Value Proposition Summary

Kiromic Leadership Team

Pietro Bersani
CPA, CGMA
CHIEF EXECUTIVE OFFICER
(interim)

Scott Dahlbeck
MD, PharmD
CHIEF OF STAFF OFFICER

Dan Clark
CPA, MBA
CHIEF FINANCIAL OFFICER
(interim)

Michael Ryan
PhD
CHIEF BIOINFORMATICS RESEARCH COMPUTING OFFICER

Kiromic Board of Directors

Michael Nagel	Pietro Bersani CPA, CGMA	Americo Cicchetti	Frank Tirelli	Karen Reeves MD
Chairperson	Director	Independent Director	Independent Director	Independent Director

Kiromic Financial Information

Balance Sheet Summary *As of December 31, 2021*	**Capitalization Table (in shares, unless otherwise stated)** *As of March 31, 2022*
Cash $25,353,900	Shares of Common Stock 15,585,587
Total Assets $30,729,600	Representative Warrants Outstanding* 400,000 Exercise price of $6.25 62,500 Exercise Price of $15.00
Total Liabilities $3,409,800	Stock Options Outstanding 367,244 Weighted Average Exercise Price of $8.49
Stockholders' Equity $27,319,800	Restricted Stock Units Outstanding 398,087 Grant Date Fair Value of $7.67


KIROMIC
BioPharma
Revolutionizing CAR-T Therapy
April 2022
NASDAQ: KRBP
Kiromic.com